PT - JOURNAL ARTICLE AU - Fong, Youyi AU - McDermott, Adrian B. AU - Benkeser, David AU - Roels, Sanne AU - Stieh, Daniel J. AU - Vandebosch, An AU - Gars, Mathieu Le AU - Van Roey, Griet A. AU - Houchens, Christopher R. AU - Martins, Karen AU - Jayashankar, Lakshmi AU - Castellino, Flora AU - Amoa-Awua, Obrimpong AU - Basappa, Manjula AU - Flach, Britta AU - Lin, Bob C. AU - Moore, Christopher AU - Naisan, Mursal AU - Naqvi, Muhammed AU - Narpala, Sandeep AU - O’Connell, Sarah AU - Mueller, Allen AU - Serebryannyy, Leo AU - Castro, Mike AU - Wang, Jennifer AU - Petropoulos, Christos J. AU - Luedtke, Alex AU - Hyrien, Ollivier AU - Lu, Yiwen AU - Yu, Chenchen AU - Borate, Bhavesh AU - van der Laan, Lars W. P. AU - Hejazi, Nima S. AU - Kenny, Avi AU - Carone, Marco AU - Wolfe, Daniel N. AU - Sadoff, Jerald AU - Gray, Glenda E. AU - Grinsztejn, Beatriz AU - Goepfert, Paul A. AU - Little, Susan J. AU - Paiva de Sousa, Leonardo AU - Maboa, Rebone AU - Randhawa, April K. AU - Andrasik, Michele P. AU - Hendriks, Jenny AU - Truyers, Carla AU - Struyf, Frank AU - Schuitemaker, Hanneke AU - Douoguih, Macaya AU - Kublin, James G. AU - Corey, Lawrence AU - Neuzil, Kathleen M. AU - Carpp, Lindsay N. AU - Follmann, Dean AU - Gilbert, Peter B. AU - Koup, Richard A. AU - Donis, Ruben O. AU - , AU - , AU - , AU - , TI - Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial AID - 10.1101/2022.04.06.22272763 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.06.22272763 4099 - http://medrxiv.org/content/early/2022/04/12/2022.04.06.22272763.short 4100 - http://medrxiv.org/content/early/2022/04/12/2022.04.06.22272763.full AB - Anti-spike IgG binding antibody, anti-receptor binding domain IgG antibody, and pseudovirus neutralizing antibody measurements four weeks post-vaccination were assessed as correlates of risk of moderate to severe-critical COVID-19 outcomes through 83 days post-vaccination and as correlates of protection following a single dose of Ad26.COV2.S COVID-19 vaccine in the placebo-controlled phase of ENSEMBLE, an international, randomized efficacy trial. Each marker had evidence as a correlate of risk and of protection, with strongest evidence for 50% inhibitory dilution (ID50) neutralizing antibody titer. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; p=0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43, 72%) at nonquantifiable ID50 (< 2.7 IU50/ml) and rose to 89% (78, 96%) at ID50 = 96.3 IU50/ml. Comparison of the vaccine efficacy by ID50 titer curves for ENSEMBLE-US, the COVE trial of the mRNA-1273 vaccine, and the COV002-UK trial of the AZD1222 vaccine supported consistency of the ID50 titer correlate of protection across trials and vaccine types.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/downloads/coi_disclosure.docx and declare: P.B.G., Y.F., D.B., A.L., O.H., Y.L., C.Y., B.B., L.W.P.v.d.L., A.K., M.C., A.K.R., M.P.A., J.G.K., L.C., and L.N.C. had support (in the form of grant payments to their institutions) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for the submitted work; O.A.-A. had support from the NIH Vaccine Immunology Program for the submitted work; C.J.P. had support from BARDA for the contract testing provided by Labcorp-Monogram Biosciences for the submitted work and is a shareholder in and corporate officer of Labcorp; A.L. declares support (in the form of grant payments to his institution) within the past 36 months from Janssen Pharmaceuticals for work on the HVTN 706 HIV vaccine efficacy trial and from the World Health Organization for writing the statistical analysis plan for the WHO's Solidarity Trial for COVID-19 vaccines, as well as consulting fees within the past 36 months received from Harvard Medical School for statistical consulting on individualized medicine software; N.S.H. had support (in the form of payments to his institution) from the National Science Foundation for the submitted work; S.R. had partial support from the Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) (in the form of contract payments to his institution) for the submitted work, has stock and/or stock options in Johnson & Johnson, and is an employee of Janssen; D.J.S. had partial support from BARDA (in the form of contract payments to his institution) for the submitted work, has stock and/or stock options in Johnson & Johnson, and is an employee of Janssen; A.V. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, had all patent rights transferred to Johnson & Johnson, has stock and/or stock options in Johnson & Johnson, and is an employee of Janssen; M.L.G. had partial support from BARDA (in the form of contract payments to his institution) for the submitted work, has shares in Johnson & Johnson, and is an employee of Johnson & Johnson; G.A.V.R. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, has stock and/or stock options in Johnson & Johnson, and is an employee of Janssen; M.C. declares an honorarium from Pfizer within the past 36 months for serving on a scientific panel to evaluate submitted funding proposals on use of talazoparib in prostate cancer submitted in response to a joint call by the National Comprehensive Cancer Network and Pfizer; J.S. declares support for the submitted work from the Janssen Pharmaceutical Companies of Johnson & Johnson and partial support (in the form of funding to his institution) from BARDA for the submitted work, declares support within the past 36 months from the Janssen Pharmaceutical Companies of Johnson & Johnson and BARDA funding for part of this work, has patents on invention of the Janssen COVID-19 vaccine, and has Johnson & Johnson stock and stock options; G.E.G. declares payment for speaking at a Johnson and Johnson-sponsored session at a conference within the past 36 months (payment donated to charity) and for serving on the Johnson and Johnson COVID-19 Vaccine Advisory Board (fees donated to charity), as well as receipt of 500,000 doses of Ad26.COV2.S vaccine donated by the United States Government/Johnson and Johnson for the Sisonke study; B.G. received consulting fees from Janssen within the past 36 months and declares receiving payments from Merck, Janssen, and GSK within the last 36 months for participation on advisory boards, as well as receipt of Truvada provided to her institution from Gilead within the past 36 months for a PrEP demonstration project; P.A.G. declares support (in the form of grant payments to his institution) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health within the past 36 months and consulting fees from Johnson and Johnson in the past 36 months; J.H. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a shareholder of Janssen Pharmaceuticals, and is an employee of Janssen Pharmaceuticals, C.T. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, holds stock in Janssen Pharmaceuticals, and is an employee of Janssen Pharmaceuticals; F.S. had partial support from BARDA (in the form of contract payments to his institution) for the submitted work, has restricted shares in Johnson & Johnson as part of compensation for employment, has shares in GlaxoSmithKline as compensation for past employment, and is employed by Johnson & Johnson; H.S. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a holder of Johnson & Johnson stock, and is an employee of Janssen Vaccines & Prevention BV; M.D. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a shareholder of Johnson & Johnson stock (has Johnson & Johnson Company stocks and stock options), and is an employee of Johnson & Johnson; K.M.N. declares grants paid to her institution within the past 36 months from Pfizer to conduct clinical trials of COVID vaccines (no salary support from this grant received) and support (in the form of grant payments to her institution) within the past 36 months from the National Institutes of Health; P.B.G. is a member of the BMGF COVID-19 Correlates Working Group (unpaid/no compensation); R.A.K. had support (in the form of intramural funding from NIAID) for the submitted work; R.O.D. declares that BARDA provided funding to Janssen and to Monogram Biosciences for the submitted work. All other authors declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. Funding StatementThis work was partially funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Government Contract Nos. HHSO100201700018C with Janssen and 75A50122C00008 with Labcorp - Monogram Biosciences; by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) under Public Health Service Grants UM1 AI068635 (HVTN SDMC), UM1 AI068614 (HVTN LOC), and R37AI054165; and by the Intramural Research Program of the NIAID Scientific Computing Infrastructure at Fred Hutch, under ORIP grant S10OD028685. This work was also supported by Janssen Research and Development, an affiliate of Janssen Vaccines and Prevention and part of the Janssen pharmaceutical companies of Johnson & Johnson. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Department of Health and Human Services or its components. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COV3001 (ENSEMBLE) study was reviewed and approved by the following local ethics committees and IRBs: Argentina: ANMAT - Administración Nacional de Medicamentos, Alimentos y Tecnologia Médica (Capital Federal, La Plata, Ramos Mejia - Buenos Aires; Ciudad Autonoma de Buenos Aires), Comite de Etica Dr Carlos Barclay (Capital Federal, Buenos Aires; Ciudad Autonoma de Buenos Aires), Comision Conjunta de Investigacion en Salud - CCIS (La Plata, Ramos Mejia - Buenos Aires), Comite de Bioetica de Fundacion Huesped (Ciudad Autonoma de Buenos Aires), Comité de Docencia e Investigación DIM Clínica Privada (Ramos Mejia, Buenos Aires), Comité de Ética en Investigación Clínica y Maternidad Suizo Argentina (Ciudad Autonoma de Buenos Aires), Comité de Ética en Investigación de CEMIC (Ciudad Autonoma de Buenos Aires), Comite de Etica en Investigacion DIM Clinica Privada (Ramos Mejia, Buenos Aires), Comite de Etica Hospital Italiano de La Plata (La Plata, Buenos Aires), Comite de Etiica en Investigacion Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires), Comité de Ética del Instituto Médico Platense (CEDIMP) (La Plata, Buenos Aires), IBC Fundacion Huesped (Ciudad Autonoma de Buenos Aires), IBC Helios Salud (Ciudad Autonoma de Buenos Aires), IBC Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires). Chile: Comité de Ética de Investigación en Seres Humanos (Santiago, Region Met), Comité Ético Científico Servicio de Salud Metropolitano Central (Santiago, Region Met), Instituto de Salud Pública de Chile (Santiago, Region Met; Talca, Temuco), Comité Ético-Científico Servicio de Salud Metropolitano Sur Oriente (Talca, Santiago), Comité de Evaluación Ética Científica Servicio de Salud Araucanía Sur Temuco (Temuco), Comité Ético Científico Servicio de Salud Metropolitano Central (Viña del Mar). Colombia: CEI de la Fundación Cardiovascular de Colombia (Floridablanca), Comité de Ética en Investigación Clínica de la Costa (Barranquilla), INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Santa Marta), Comite de Etica en la Investigacion CAIMED (Bogotá), INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Bogotá), Comite Corporativo de Etica en Investigacion de la Fundacion Santa Fe de Bogota (Bogotá), Comité de Ética e Investigación BiomÉdica de la Fundación Valle del Lili (Cali), Comite de Etica e Investigacion IPS Universitaria (Medellin), Comite de Etica en Investigacion Asustencial Cientifica de Alta Complejidad (Bogotá), Comite de Etica en Investigacion Biomedica de la Corporacion Cientifica Pediatrica de Cali (Cali), Comité de Ética en Investigación Clínica de la Costa (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Barrio Barzal Villavicencio), Comite de Etica en Investigacion del area de la Salud de la Universidad del Norte (Barranquilla), Comite de Etica en Investigacion Medplus Centro de Recuperación Integral S.A.S (Bogotá), Comité de Ética en Investigaciones CEI-FOSCAL (Floridablanca), Comite de Etica en la Investigacion CAIMED (Bogotá), Comite de Etica para Investigacion Clinica(CEIC) de la Fundacion Centro de Investigacion Clinica CIC (Medellin), Comite de Investigaciones y Etica en Investigaciones Hospital Pablo Tobon Uribe (Medellin), INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla, Bogotá, Cali, Floridablanca, Medellin. Mexico: CEI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CEI Hospital La Mision (Tijuana, Baja California Norte), CI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CI Hospital La Mision (Tijuana, Baja California Norte), Comite de Bioseguridad del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comite de Etica en Investigacion del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comité de Bioseguridad del Hospital La Misión S.A. de C.V. (Tijuana, Baja California Norte; Oaxaca, Oaxaca; Merida, Yucatán; Tijuana, Baja California Norte), Comité de Bioseguridad de la Coordinación de Investigación en Salud (IMSS) (Mexico, Estado de Mexico), Comité de Bioseguridad de Médica Rio Mayo (CLINBOR) (Mexico, Distrito Federal), Comité de Bioseguridad del Hospital Universitario "Dr. José Eleuterio González" (Monterrey, Nuevo León), COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) (Cuernavaca, Morelos; Mexico, Distrito Federal; Monterrey, Nuevo León; Oaxaca, Oaxaca; Merida, Yucatán), Comite de Etica de la Fac de Med de la UANL y Hospital Universitario "Dr. Jose Eleuterio Gonzalez" (Monterrey, Nuevo León), Comite de Etica en Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucatán), Comite de Etica en Investigacion de Medica Rio Mayo S.C. (Mexico, Distrito Federal), Comite de Etica en Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comite de Etica en Investigacion del Centro Medico Nacional Siglo XXI (IMSS) (Mexico, Estado do Mexico), Comité de Investigación de la Coordinación de Investigación en Salud (IMSS) (Mexico, Estado do Mexico), Comite de Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucatán), Comite de Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comité de Investigación del Hospital Universitario José Eleuterio González (Monterrey, Nuevo León), Comite de Investigacion Medica Rio Mayo, S.C. (Mexico, Distrito Federal). Peru: Comite Nacional Transitorio de Etica en Invest. de los Ensayos Clinicos de la enfermedad COVID-19 (Iquitos - Maynas, Loreto; Lima, San Miguel - Lima), INS - Instituto Nacional de Salud (Peru) (Lima, San Miguel - Lima; Callao; Iquitos - Maynas, Loreto). South Africa: Department Agriculture, Forestry and Fisheries (DAFF) (Port Elizabeth, Mthatha - Eastern Cape; Cape Town, Worcester - Western Cape; Durban, Ladysmith, Vulindlela - KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa - Gauteng; Rustenburg, Klerksdorp - North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), Pharma Ethics (Port Elizabeth, Eastern Cape; Durban, Ladysmith - KwaZulu-Natal; Cape Town, Western Cape; Pretoria, Mamelodi East, Johannesburg, Tembisa - Gauteng; Rustenburg, Klerksdorp - North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), SAHPRA - South African Health Products Regulatory Authority (Port Elizabeth, Mthatha - Eastern Cape; Cape Town, Worcester - Western Cape; Durban, Ladysmith, Vulindlela - KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa - Gauteng; Rustenburg, Klerksdorp - North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), WIRB (Mamelodi East, Pretoria - Gauteng; Ladysmith, KwaZulu-Natal; Bloemfontein, Free State; Cape Town, Western Cape; Dennilton, Limpopo), Wits Health Consortium (Soweto, Johannesburg - Gauteng; Ladysmith, KwaZulu-Natal; Mthatha, Eastern Cape), Wits Institutional Biosafety Committee (Soweto, Pretoria, Johannesburg, Tembisa - Gauteng; Rustenburg, Klerksdorp - North West; Mthatha, Eastern Cape), University of Cape Town HREC (Cape Town, Worcester - Western Cape); University of Cape Town Institute of Infectious Disease & Molecular Medicine (Cape Town, Worcester - Western Cape), University of Cape Town Institutional Biosafety Committee (Cape Town, Worcester - Western Cape), SAMRC Human Research Ethics Committee Scientific Review (Durban, KwaZulu-Natal), Sefako Makgatho University Research Ethics Committee (SMUREC) (Pretoria, Gauteng), University of KwaZulu Natal Institutional Biosafety Committee (Durban, KwaZulu-Natal), University of KwaZulu-Natal Ethics (Durban, Vulindlela - KwaZulu-Natal), University of Stellenbosch Ethics Committee (Cape Town, Western Cape), University of KwaZulu Natal Institutional Biosafety Committee (Vulindlela, KwaZulu-Natal). United States: Advarra IBC (Detroit, MI; Chapel Hill, NC; Boston, MA; Seattle, WA; Winston-Salem, NC; Austin, TX; Peoria, IL; Huntsville, AL; Long Beach, CA; Tucson, AZ), Biomedical Institute of New Mexico - IBC (Albuquerque, NM), Birmingham VA Medical Center - Alabama- IBC (Birmingham, AL), Clinical Biosafety Services (Hollywood, FL), Columbia University IBC (New York, NY), Copernicus Group IRB (Austin, Dallas, Houston, San Antonio - TX; Rochester, New York, Bronx, Binghamton - NY; Hillsborough, Hackensack, Newark, New Brunswick - NJ; West Palm Beach, Coral Gables, Hollywood, Miami, Orlando, Gainesville, Tampa, Hallandale Beach, Pinellas Park, The Villages, Jacksonville, Deland - FL; Fort Worth, Dallas, San Antonio - TX; Norfolk, Charlottesville - VA; Matairie, New Orleans - LA; Nashville, Knoxville, Memphis, Bristol - TN; Cincinnati, Cleveland, Columbus, Akron - OH; Detroit, Ann Arbor, Grand Rapids - MI; Philadelphia, Pittsburgh - PA; Stanford, San Diego, San Francisco, Oakland, Long Beach, Anaheim, Sacramento, West Hollywood - CA, Las Vegas, Reno - NV; Chicago, Peoria - IL; Omaha, NE; Mobile, Birmingham, Huntsville - AL; St Louis, Greer, Kansas City - MO; Boston, MA; Harrisburg, SD; Decatur, Atlanta, Savannah - GA; Baltimore, Rockville, Annapolis - MD; New Haven, Hartford - CT; Chapel Hill, Raleigh, Fayetteville, Charlotte, Durham, Winston-Salem - NC; Indianapolis, Valparaiso, Evansville - IN; Seattle, WA; Aurora, CO; Lexington, Louisville - KY; Murray, West Jordan, Salt Lake City - UT; Phoenix, Tucson, Glendale - AZ; Spartanburg, Columbia, North Charleston, Anderson, Charleston, Mount Pleasant - SC; Portland, Medford, Corvallis - OR; Albuquerque, Gallup - NM; Little Rock, AR; Jackson, MS; Newport News, VA, Minneapolis, MN; Lenexa, KS), WIRB (Hackensack, NJ; Dallas, TX; Baltimore, MD; Chicago, IL; Aurora, CO; Winston-Salem, NC; Minneapolis, MN; Orlando, Miami, Gainesville - FL; Philadelphia, Pittsburgh - PA; Boston, MA; St Louis, MO; Bronx, New York, NY; New Brunswick, NJ; Phoenix, AZ; Birmingham, AL; Louisville, KY; Albuquerque, NM; New Orleans, LA; Baltimore, MD; San Francisco, CA; Tampa, FL; Aurora, CO; Columbia, SC; Decatur, GA; Reno, NV; Raleigh, NC; Little Rock, AS), Clinical Biosafety Services (Dallas, San Antonio - TX; San Diego, CA; Lexington, KY; Murray, UT; Greer, Kansas City, St Louis - MO; Rockville, MD; Las Vegas, NV; Cincinnati, Columbus, Akron - OH; Phoenix, Tucson, Glendale - AZ; North Charleston, Anderson - SC; Orlando, Pinellas Park, The Villages, Miami - FL; Birmingham, AL; Valparaiso, Evansville - IN; Lenexa, KS), Columbia University IBC (Bronx, New York), Durham VA Medical Center-IBC (Raleigh, NC), Emory University IRB (Decatur, GA), Environmental Health and Safety Office (Atlanta, GA), Institutional Biosafety Committee (New Orleans, LA), James A. Haley Veterans Hospital_IBC (Tampa, FL), Jesse Brown VA Medical Center- IBC (Chicago, IL), Mass General Brigham IBC (Boston, MA), Mount Sinai- Icahn School of Medicine IBC (New York, NY), New York Blood Center IBC (New York, NY), OHSU IBC (Portland, OR), Partners Institutional Biosafety Committee (Boston, MA), Rocky Mountain Regional VA Medical Center-IBC (Aurora, CO), Rush University Medical Center (Chicago, IL), Rush University Medical Center IBC (Chicago, IL), Rutgers Institutional Biosafety Committee (New Brunswick, NJ), Saint Louis University IBC (St Louis, MO), Saint Michael's Medical Center IRB (Newark, NJ), Southeast Louisiana Veterans Health Care System IBC (New Orleans, LA), St. Jude Children's Research Hospital IBC Committee (Memphis, TN), St. Jude Children's Research Hospital IRB (Memphis, TN), Stanford University Administrative Panel on Human Subjects in Medical Research (Stanford, CA), Temple University - IBC (Philadelphia, PA), The University of Chicago Institutional Biosafety Committee (Chicago, IL), UAMS IBC (Little Rock, AS), UIC IBC (Chicago, IL), University of Alabama at Birmingham Institutional Biosafety Committee (Birmingham, AL), University of Arkansas IRB (Little Rock, AS), University of Kentucky Biological Safety (Lexington, KY), University of Kentucky IRB (Lexington, KY), University of Louisville IRB (Louisville, KY), University of Miami-IBC (Miami, FL), University of Mississippi Medical Center IRB (Jackson, MI), University of Pennsylvania Institutional Biosafety Committee (Philadelphia, PA), University of Pittsburgh IBC (Pittsburgh, Pennsylvania), University of South Florida IRB (Tampa, FL), University of Utah Institutional Biosafety Committee (Salt Lake City, UT), University of Utah IRB (Salt Lake City, UT), UTHealth - IBC (Houston, TX), VA Baltimore Research & Education Foundation (BREF)- IBC (Baltimore, MD), VA Central Arkansas Veterans Healthcare System-IBC (Little Rock, AS), VA James J. Peters Department of VA Medical Center-IBC (Bronx, NY), VA Medical Center - Atlanta-IBC (Decatur, GA), VA Medical Center San Francisco- IBC (San Francisco, CA), VA North Florida/South Georgia IBC (Gainesville, FL), VA North Texas Health Care System IBC (Dallas, TX), VA San Diego Healthcare System IBC (Phoenix, AZ), VA Sierra Nevada Health Care System-IBC (Reno, NV), Vanderbilt University Instituitional Review Board (Nashville, TN), Washington University IBC (St Louis, MO), WCG IBCS (Houston, TX; Orlando, FL), Western Institutional Review Board (San Diego, CA; Detroit, MI; New Orleans, LA; New York, NY), WIRB - IBCS Services (Chicago, IL; New Orleans, LA; Oakland, CA; Minneapolis, MN; Columbus, OH; Lexington, KY), WJB Dorne VA Medical Center IBC (Columbia, SC). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete de-identified patient data set will be made available to others. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.